DG-041 | CAS# 861238-35-9 |EP3 receptor antagonist |MedKoo

DG-041
featured

WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 531761

CAS#: 861238-35-9

Description: DG-041 is a potent and selective prostanoid EP3 receptor antagonist. It is a new target for inhibition of platelet function in atherothrombotic disease.

Chemical Structure

DG-041

CAS# 861238-35-9

Product data Instruction

Theoretical Analysis

MedKoo Cat#: 531761
Name: DG-041
CAS#: 861238-35-9
Chemical Formula: C23H15Cl4FN2O3S2
Exact Mass: 589.93
Molecular Weight: 592.300
Elemental Analysis: C, 46.64; H, 2.55; Cl, 23.94; F, 3.21; N, 4.73; O, 8.10; S, 10.83

Price and Availability

Size	Price	Availability
10mg	USD 365	2 Weeks
50mg	USD 1235	2 Weeks
Bulk inquiry Welcome, Customer: Please do not inquire quote if your intended use is for a patient since our products are for research use and for chemical synthesis use, not for human use . For in-stock products, we listed price in the web page. You may inquire prices for which sizes were not listed. If no price is listed, this means the product is not in stock at the moment, which may be available via custom synthesis. For cost-effective reason, minimum order of 1g is requested (typically very expensive). The lead time is usually 2-4 months. Quote of less than 1g will not be provided. MedKoo may not offer quote for below reasons: (1) current available synthetic method appears to be extremely expensive which is obviously not affordable to most customers; (2) Key raw material to make the product is temporally not available; (3) DEA controlled substances; (4) the product is under patent protection in customer’s country.

Synonym: DG-041; DG 041; DG041.

IUPAC/Chemical Name: (E)-3-[1-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methylindol-7-yl]-N-(4,5-dichlorothiophen-2-yl)sulfonylprop-2-enamide

InChi Key: BFBTVZNKWXWKNZ-HWKANZROSA-N

InChi Code: InChI=1S/C23H15Cl4FN2O3S2/c1-12-10-30(11-14-2-4-15(24)7-18(14)25)22-13(6-16(28)8-17(12)22)3-5-20(31)29-35(32,33)21-9-19(26)23(27)34-21/h2-10H,11H2,1H3,(H,29,31)/b5-3+

SMILES Code: O=C(NS(=O)(C1=CC(Cl)=C(Cl)S1)=O)/C=C/C2=CC(F)=CC3=C2N(CC4=CC=C(Cl)C=C4Cl)C=C3C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Product Data:

Product Data

Instruction:

View handling instruction

Biological target:	Potent and selective EP3 antagonist; antiplatelet and antithrombotic.
In vitro activity:	DG-041 antagonized the effects of sulprostone on platelet function. The effect of PGE(2) on platelet aggregation depended on the nature of the agonist and the concentration of PGE(2) used as a consequence of both pro-aggregatory effects via EP3 and anti-aggregatory effects via other receptors. DG-041 potentiated the protective effects of PGE(2) on platelet aggregation by inhibiting the pro-aggregatory effect via EP3 stimulation. Reference: Platelets. 2008 Dec;19(8):605-13. https://pubmed.ncbi.nlm.nih.gov/19012178/
In vivo activity:	Following the measurement of baseline blood pressure, 10 μg/kg sulprostone was administered IV via the jugular catheter which caused a rise in mean arterial pressure (MAP) in vehicle treated mice (Figure 2E). This study has previously shown that sulprostone and other EP3 agonists cause a rise in MAP. The DG-041 treatment effectively blocked the sulprostone-evoked change in MAP (Figure 2E). In subsequent studies DG-041 was administered via SC injections at 20 mg/kg twice daily, which would provide plasma concentrations sufficient to achieve full coverage of the EP3 receptors. Reference: Prostaglandins Other Lipid Mediat. 2019 Oct; 144: 106353. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6778036/

Solubility Data

	Solvent	Max Conc. mg/mL	Max Conc. mM
Solubility
	DMSO	59.2	100.00

Preparing Stock Solutions

The following data is based on the product molecular weight 592.30 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:	1. Singh J, Zeller W, Zhou N, Hategan G, Mishra RK, Polozov A, Yu P, Onua E, Zhang J, Ramírez JL, Sigthorsson G, Thorsteinnsdottir M, Kiselyov AS, Zembower DE, Andrésson T, Gurney ME. Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. J Med Chem. 2010 Jan 14;53(1):18-36. doi: 10.1021/jm9005912. PMID: 19957930. 2. Heptinstall S, Espinosa DI, Manolopoulos P, Glenn JR, White AE, Johnson A, Dovlatova N, Fox SC, May JA, Hermann D, Magnusson O, Stefansson K, Hartman D, Gurney M. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease. Platelets. 2008 Dec;19(8):605-13. doi: 10.1080/09537100802351073. PMID: 19012178. 3. Ceddia RP, Downey JD, Morrison RD, Kraemer MP, Davis SE, Wu J, Lindsley CW, Yin H, Daniels JS, Breyer RM. The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesity. Prostaglandins Other Lipid Mediat. 2019 Oct;144:106353. doi: 10.1016/j.prostaglandins.2019.106353. Epub 2019 Jul 2. PMID: 31276827; PMCID: PMC6778036. 4. Tilly P, Charles AL, Ludwig S, Slimani F, Gross S, Meilhac O, Geny B, Stefansson K, Gurney ME, Fabre JE. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Cardiovasc Res. 2014 Mar 1;101(3):482-91. doi: 10.1093/cvr/cvt276. Epub 2013 Dec 9. PMID: 24323317.
In vitro protocol:	1. Singh J, Zeller W, Zhou N, Hategan G, Mishra RK, Polozov A, Yu P, Onua E, Zhang J, Ramírez JL, Sigthorsson G, Thorsteinnsdottir M, Kiselyov AS, Zembower DE, Andrésson T, Gurney ME. Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-dichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. J Med Chem. 2010 Jan 14;53(1):18-36. doi: 10.1021/jm9005912. PMID: 19957930. 2. Heptinstall S, Espinosa DI, Manolopoulos P, Glenn JR, White AE, Johnson A, Dovlatova N, Fox SC, May JA, Hermann D, Magnusson O, Stefansson K, Hartman D, Gurney M. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease. Platelets. 2008 Dec;19(8):605-13. doi: 10.1080/09537100802351073. PMID: 19012178.
In vivo protocol:	1. Ceddia RP, Downey JD, Morrison RD, Kraemer MP, Davis SE, Wu J, Lindsley CW, Yin H, Daniels JS, Breyer RM. The effect of the EP3 antagonist DG-041 on male mice with diet-induced obesity. Prostaglandins Other Lipid Mediat. 2019 Oct;144:106353. doi: 10.1016/j.prostaglandins.2019.106353. Epub 2019 Jul 2. PMID: 31276827; PMCID: PMC6778036. 2. Tilly P, Charles AL, Ludwig S, Slimani F, Gross S, Meilhac O, Geny B, Stefansson K, Gurney ME, Fabre JE. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Cardiovasc Res. 2014 Mar 1;101(3):482-91. doi: 10.1093/cvr/cvt276. Epub 2013 Dec 9. PMID: 24323317.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.

Mass

Concentration

Volume

M. Wt* g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

Volume (to add to vial)

Mass (in vial)

Desired Reconstitution Concentration

Dilution Calculator

Calculate the dilution required to prepare a stock solution.

Concentration 1

Volume 1

Concentration 2

Volume 2

1: Tilly P, Charles AL, Ludwig S, Slimani F, Gross S, Meilhac O, Geny B, Stefansson K, Gurney ME, Fabre JE. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Cardiovasc Res. 2014 Mar 1;101(3):482-91. doi: 10.1093/cvr/cvt276. PubMed PMID: 24323317.

2: Singh J, Zeller W, Zhou N, Hategan G, Mishra RK, Polozov A, Yu P, Onua E, Zhang J, Ramírez JL, Sigthorsson G, Thorsteinnsdottir M, Kiselyov AS, Zembower DE, Andrésson T, Gurney ME. Structure-activity relationship studies leading to the identification of (2E)-3-[l-[(2,4-dichlorophenyl)methyl]-5-fluoro-3-methyl-lH-indol-7-yl]-N-[(4,5-d ichloro-2-thienyl)sulfonyl]-2-propenamide (DG-041), a potent and selective prostanoid EP3 receptor antagonist, as a novel antiplatelet agent that does not prolong bleeding. J Med Chem. 2010 Jan 14;53(1):18-36. doi: 10.1021/jm9005912. PubMed PMID: 19957930.

3: Heptinstall S, Espinosa DI, Manolopoulos P, Glenn JR, White AE, Johnson A, Dovlatova N, Fox SC, May JA, Hermann D, Magnusson O, Stefansson K, Hartman D, Gurney M. DG-041 inhibits the EP3 prostanoid receptor--a new target for inhibition of platelet function in atherothrombotic disease. Platelets. 2008 Dec;19(8):605-13. doi: 10.1080/09537100802351073. PubMed PMID: 19012178.

Your view history

DG-041 featured